[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201907102XA - Immunological biomarker for predicting clinical effect of cancer immunotherapy - Google Patents

Immunological biomarker for predicting clinical effect of cancer immunotherapy

Info

Publication number
SG11201907102XA
SG11201907102XA SG11201907102XA SG11201907102XA SG11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA
Authority
SG
Singapore
Prior art keywords
cancer immunotherapy
clinical effect
predicting clinical
immunological biomarker
biomarker
Prior art date
Application number
SG11201907102XA
Inventor
Hiroshi Kagamu
Original Assignee
Univ Saitama Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saitama Medical filed Critical Univ Saitama Medical
Publication of SG11201907102XA publication Critical patent/SG11201907102XA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57Skin; melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514CD4
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564Selectins, e.g. CD62
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201907102XA 2017-02-07 2018-02-06 Immunological biomarker for predicting clinical effect of cancer immunotherapy SG11201907102XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017020685 2017-02-07
JP2017110069 2017-06-02
PCT/JP2018/004090 WO2018147291A1 (en) 2017-02-07 2018-02-06 Immunological biomarker for predicting clinical effect of cancer immunotherapy

Publications (1)

Publication Number Publication Date
SG11201907102XA true SG11201907102XA (en) 2019-08-27

Family

ID=61527481

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907102XA SG11201907102XA (en) 2017-02-07 2018-02-06 Immunological biomarker for predicting clinical effect of cancer immunotherapy

Country Status (13)

Country Link
US (3) US11293924B2 (en)
EP (2) EP3580569B1 (en)
JP (4) JP6664684B1 (en)
KR (2) KR102617574B1 (en)
CN (2) CN110446928B (en)
AU (1) AU2018218844B2 (en)
CA (1) CA3052027A1 (en)
IL (1) IL268524A (en)
MX (1) MX2019009386A (en)
SG (1) SG11201907102XA (en)
TW (2) TWI795386B (en)
UY (1) UY37594A (en)
WO (1) WO2018147291A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907102XA (en) 2017-02-07 2019-08-27 Univ Saitama Medical Immunological biomarker for predicting clinical effect of cancer immunotherapy
CA3074751A1 (en) 2017-09-12 2019-03-21 ImmuneSignatures Pty Ltd Predicting responses to immunotherapy
CN113330310A (en) * 2018-11-09 2021-08-31 皮埃里亚生物科学有限责任公司 Methods and compositions for determining tumor microenvironment composition
TW202035702A (en) * 2019-02-20 2020-10-01 學校法人埼玉醫科大學 Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy
WO2020171141A1 (en) 2019-02-20 2020-08-27 学校法人 埼玉医科大学 Method and composition for predicting long-term survival in cancer immunotherapy
EP3953712A1 (en) * 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
JP6796737B1 (en) * 2020-06-02 2020-12-09 振武 曽 Multi-item automatic blood cell counter
US20240264158A1 (en) * 2020-09-08 2024-08-08 Saitama Medical University Biomarker for predicting response to cancer treatment
CN112114129A (en) * 2020-09-25 2020-12-22 苏州大学 Method for detecting tumor specific T cells
AU2020469045A1 (en) * 2020-09-25 2023-04-27 Suzhou Ersheng Biopharmaceutical Co., Ltd Detection method for tumor-specific t cells
WO2022215843A1 (en) * 2021-04-06 2022-10-13 (주)에스엠티바이오 Method for predicting therapeutic response of cancer patient to anticancer immunotherapy using natural killer cells
WO2023083924A1 (en) * 2021-11-10 2023-05-19 Institut Gustave Roussy Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapy
CN114354931B (en) * 2021-12-14 2023-03-14 南方医科大学南方医院 Application of splenomegaly in determining curative effect of tumor patient immune checkpoint inhibitor treatment
US12013816B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Querying metadata in a storage system
US12013857B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Identifying hot items in a distributed storage system
WO2023230548A1 (en) * 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2024185887A1 (en) * 2023-03-08 2024-09-12 イミュニティリサーチ株式会社 System, method, and program for specifying cell population

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP2006280307A (en) * 2005-04-01 2006-10-19 Kyoto Univ Method for producing controllable t cell
ATE483470T1 (en) * 2005-12-21 2010-10-15 Sentoclone Ab METHOD FOR EXPANSION OF TUMOR-REACTIVE T-LYMPHOCYTES FOR IMMUNOTHERAPY OF PATIENTS WITH CANCER
EP2173438A2 (en) * 2007-07-13 2010-04-14 Genentech, Inc. Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
EP2215220B1 (en) * 2007-11-08 2018-01-10 Dana-Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20120088678A1 (en) * 2010-09-08 2012-04-12 Sanford-Burnham Medical Research Institute Method for prediction of response to rheumatoid arthritis therapeutics
CN103502438A (en) * 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 Method and compositions for cellular immunotherapy
CA2840424C (en) * 2011-07-01 2022-02-01 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
AR092423A1 (en) * 2012-09-04 2015-04-22 Univ Niigata METHOD OF DIAGNOSIS AND TREATMENT OF CANCER DIRECTED TO MOLECULES EXPRESSED IN CANCEROSA MOTHER CELLS
EP3552628A1 (en) 2012-09-07 2019-10-16 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
EP3060919A4 (en) 2013-10-25 2018-02-14 Nodality, Inc. Methods and compositions for immunomodulation
EP3197495A4 (en) 2014-09-28 2018-08-29 The Regents of The University of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016172010A1 (en) * 2015-04-20 2016-10-27 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
CA2991044A1 (en) * 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
EP3417293A1 (en) 2016-02-18 2018-12-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
EP3576757B1 (en) 2017-02-06 2021-06-09 Novartis AG Method of predicting response to immunotherapy
SG11201907102XA (en) 2017-02-07 2019-08-27 Univ Saitama Medical Immunological biomarker for predicting clinical effect of cancer immunotherapy
US20200393469A1 (en) 2017-05-16 2020-12-17 Kurume University Method for determining eligibility of brain tumor patient for tailor-made type peptide vaccine agent

Also Published As

Publication number Publication date
KR102617574B1 (en) 2023-12-22
US20230349909A1 (en) 2023-11-02
JP2020512530A (en) 2020-04-23
CN116712458A (en) 2023-09-08
US20220178933A1 (en) 2022-06-09
TW201833551A (en) 2018-09-16
JP2024023862A (en) 2024-02-21
IL268524A (en) 2019-09-26
KR20230017355A (en) 2023-02-03
JP7067804B2 (en) 2022-05-16
TW202323820A (en) 2023-06-16
CN110446928B (en) 2023-06-20
JP2020073924A (en) 2020-05-14
WO2018147291A1 (en) 2018-08-16
EP4039260A1 (en) 2022-08-10
US20200025768A1 (en) 2020-01-23
JP6664684B1 (en) 2020-03-13
MX2019009386A (en) 2019-11-05
KR102490278B1 (en) 2023-01-18
JP2022105066A (en) 2022-07-12
AU2018218844B2 (en) 2024-08-01
KR20190112027A (en) 2019-10-02
AU2018218844A1 (en) 2019-09-19
US11293924B2 (en) 2022-04-05
EP4039260B1 (en) 2024-04-17
EP3580569B1 (en) 2022-03-09
CA3052027A1 (en) 2018-08-16
CN110446928A (en) 2019-11-12
UY37594A (en) 2018-08-31
EP3580569A1 (en) 2019-12-18
TWI795386B (en) 2023-03-11

Similar Documents

Publication Publication Date Title
IL268524A (en) Immunological biomarker for predicting clinical effect of cancer immunotherapy
EP3524689A4 (en) Method for predicting the prognosis of breast cancer patient
HK1246828A1 (en) Biomarker panel for the detection of cancer
EP3597766A4 (en) Novel biomarker for cancer immunotherapy
EP3230745A4 (en) Plasma autoantibody biomarkers for basal like breast cancer
PL3455625T3 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
GB201607393D0 (en) Biomarkers for early diagnosis of ovarian cancer
EP3201360A4 (en) Methods for assessing risk of developing breast cancer
IL270717A (en) Biomarkers for diagnosis of lung cancer
HK1248803A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
EP3204008A4 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
EP3743058A4 (en) Methods for predicting tumor response to immunotherapy
EP2998740A4 (en) Method for predicting clinical effect of immunotherapy
EP3574113A4 (en) Improved methods for assessing risk of developing breast cancer
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
EP3189332A4 (en) Biomarkers for detection of breast cancer
PT3791186T (en) Antigen biomarker of microsatellite instability
GB201617722D0 (en) Method for determining prognosis of cancer
EP3060914A4 (en) Methods of determining breast cancer prognosis
GB201908085D0 (en) Methods of determining cancer
EP3638308A4 (en) Biomarkers for predicting tumor response to and toxicity of immunotherapy
EP3440468B1 (en) Biomarkers for predicting degree of weight loss
AU2017275640A1 (en) Biomarkers for predicting degree of weight loss
AU2017905180A0 (en) Biomarker of disease
GB201414362D0 (en) Biomarkers for early diagnosis of ovarian cancer